President, AMV Advisors
Anne VanLent is the founder and president of AMV Advisors, a strategic and financial management consultancy that serves emerging-growth and early stage companies in the life sciences arena. With more than 30 years of leadership experience at research and development, biotechnology, and pharmaceutical firms, VanLent guides emerging life sciences firms in financial operations, strategic funding and transaction support, and mentoring high-potential executives.
An experienced, seasoned director and audit chair of publicly traded companies, VanLent currently serves on the board of directors of the biopharmaceutical companies Applied Genetic Technologies Corporation and Aviragen Pharmaceuticals, Inc. She also served on the boards of Novelion Therapeutics, Inc., Ocera Therapeutics, Inc., Onconova Therapeutics, Integra Life Sciences Holding Corporation, and Penwest Pharmaceuticals, among others.
Previously, she was executive vice president and chief financial officer of Barrier Therapeutics, Inc., executive vice president of portfolio management and vice president of ventures and licensing at Sarnoff Corporation, and executive vice president and chief financial officer at The Liposome Company, Inc. She holds a B.S. in physics from Mount Holyoke College.